• 5/14/26 | Article

    From Bench to Bedside: The State of Cardiovascular Innovation

    What does it take to move cardiovascular innovation from bench to bedside? Dr. Kevin Baumlin, chief medical affairs officer of the Science Center and former professor and chair of Emergency Medicine at Pennsylvania Hospital, moderated a cross-sector discussion between cardiologist Dr. Rajan Jain, associate professor of Medicine at the University
    Read Article
    Up Next:

    From Bench to Bedside: The State of Cardiovascular Innovation

  • 4/30/26 | Success Story

    A Better Way to Breathe: The Airalux Story

    We’ve all heard the adage that an ounce of prevention is worth a pound of cure. Yet, patient adherence is a complex issue with numerous factors that can make it challenging to follow clinician recommendations.
    Read Article
    Up Next:

    A Better Way to Breathe: The Airalux Story

  • 4/9/26 | Success Story

    Life on the Cutting Edge: BioCurie

    In 2023, the FDA approved the first cell-based gene therapies to treat sickle cell disease, a lifelong illness that shaves 20–25 years off average life expectancy. However, the process of collecting and genetically modifying a patient’s own blood cells is intensive, with treatments costing as much as $3.3 million. Despite
    Read Article
    Up Next:

    Life on the Cutting Edge: BioCurie

  • 3/26/26 | Article

    When Capital Is Scarce, Readiness Wins: The Signals That Separate Capital-Ready Companies

    For decades, the Science Center has worked alongside founders and investors at some of the most consequential moments in a company’s trajectory — when science is translating into a product, and when capital decisions determine whether that progress accelerates or stalls. Over time, patterns became clear.
    Read Article
    Up Next:

    When Capital Is Scarce, Readiness Wins: The Signals That Separate Capital-Ready Companies